ENSOGUARD
EnsoGuard is an artificial intelligence startup that features a software platform that protects companies from unveiling confidential data. Its platform specializes in automatic monitoring of target systems and selectively encrypting sensitive information. The company was founded in 2018 and headquartered in Yerushalayim, Israel.
ENSOGUARD
Industry:
Artificial Intelligence Cyber Security Information Technology Internet Machine Learning Software
Founded:
2018-10-01
Address:
Jerusalem, Yerushalayim, Israel
Country:
Israel
Website Url:
http://www.ensoguard.com
Status:
Active
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Bodygram
Bodygram is an AI body size estimation software and platform for enterprise users.
Elderedda
Elderedda is a software platform that specializes in NIDS, SDN, and legacy monitoring system.
RunTec
RUNTEC is a software firm & a leader in logistical monitoring of deliveries.
Talentspear
Talentspear is a new-age boutique software lab that provides cutting-edge products and solutions for customers globally.
Current Employees Featured
Founder
More informations about "EnsoGuard"
Esophageal Cancer | EsoGuard | United States
Patients in select states, including Texas, can now request an EsoGuard evaluation online. Get Started. A DNA test to detect esophageal precancer. Learn more about the EsoGuard DNA …See details»
EnsoGuard - Crunchbase Company Profile & Funding
EnsoGuard is an artificial intelligence startup that features a software platform that protects companies from unveiling confidential data. Its platform specializes in automatic monitoring of …See details»
EnsoGuard - LinkedIn
ENSOGUARD protects companies from unveiling confidential data by autonomously monitoring target systems and selectively encrypting sensitive information.See details»
Home | UpScript
The EsoGuard DNA test is performed on cells collected from your esophagus by a licensed clinician at a Lucid Test Center. Getting started is easy! After completing a short online questionnaire, one of our physicians will evaluate …See details»
New Technology Gives Patients Access to a 5-Minute, …
Jun 1, 2020 "The EsoCheck/EsoGuard combination shows how the NCI-sponsored biomarker discovery and validation process can lead to new discoveries, new technologies, and new clinical products," said Markowitz. …See details»
FDA calls New Screening Test Using DNA to Detect …
Feb 18, 2020 EsoGuard performs next generation sequencing (NGS) of bisulfite-converted DNA to detect methylation at 31 sites on two genes (VIM and CCNA1). EsoGuard has been shown in a 408-patient human study published …See details»
EsoGuard - LucidDX
3. Shaheen, N., et al., Use of the EsoGuard® Molecular Biomarker Test in Non-Endoscopic Detection of Barrett's Esophagus among High-Risk Individuals in a Screening Population. …See details»
Insurance + Billing
You can also reach out to us at 1-888-LucidDx (888-582-4339), or via email and one of our dedicated agents will be happy to pre-qualify you and assist with the application process.See details»
Lucid Diagnostics Expands Direct Contracting Initiative with …
NEW YORK, Nov. 5, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that its commercial team has embarked on an expansion of its direct contracting initiative, focusing on programs designed to …See details»
Precancer detection - LucidDX
The EsoGuard DNA test detects abnormal esophageal cells to identify disease before it progresses. With ~90% sensitivity and ~99% negative predictive value at detecting Barrett's …See details»
Lucid Diagnostics Presents Real-World EsoCheck Data at the …
Dec 1, 2022 EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of multiple ongoing clinical trials. Lucid is building nationwide …See details»
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal ...
Dec 19, 2024 Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck ...See details»
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard ...
Dec 11, 2024 This is the fourth peer-reviewed publication presenting outstanding clinical utility data for the EsoGuard® Esophageal DNA Test. In addition to demonstrating near-Lucid …See details»
EsoGuard — Early Detection Research Network
From Esoguard.com: With over 90% sensitivity and specificity at detecting BE and EAC, the EsoGuard esophageal DNA test allows detection of these conditions in a simple office-based procedure WITHOUT endoscopy. EsoGuard analyzes methylation at 31 sites on 2 genes.See details»
EsoGuard Clinical Trial
EsoGuard is a DNA test that detects abnormal esophageal cells, such as Barrett’s Esophagus, precancerous cells with dysplasia and cancer. How it works A physician performs a cell collection procedure to gather cells from your lower esophagus for analysis. The collected cells are shipped to our laboratory where the DNA is tested using the ...See details»
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected …
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to …See details»
Article - Response to Comments: MolDX: Molecular Testing for …
Mar 30, 2023 A seminal study published in Science Translational Medicine by a highly respected group of investigators led by a long-time colleague, collaborator and renowned cancer …See details»
EsoGuard Test: Early Detection of Esophageal Conditions
Nov 18, 2024 The EsoGuard esophageal DNA test is an innovative, non-invasive screening tool that utilizes non-endoscopic detection to identify conditions like Barrett’s esophagus and …See details»
Legacy Sponge-on-a-String Esophageal Cell Collection Device …
May 9, 2024 Lucid's EsoGuard ® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device - …See details»
Clinical Data - LucidDX
The EsoGuard assay was performed at the central commercial laboratory, Lucid Dx Labs, and showed high sensitivity (85%) and specificity (85%) for detecting disease. No cancers (EAC) were missed. These findings demonstrate this strategy to be practical for clinical implementation, and a viable office-based alternative to screening endoscopy for detection of BE/EAC.See details»